Search

Your search keyword '"Bertasso, Anne"' showing total 18 results
Start Over Author "Bertasso, Anne"
18 results on '"Bertasso, Anne"'

1. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study

Author

Gane, Edward J., Pockros, Paul J., Zeuzem, Stefan, Marcellin, Patrick, Shikhman, Anna, Bernaards, Coen, Zhou, Julian, Yetzer, Ellen S., Ballester, Rosa, Dwyer, Cindy, Tong, Xiao, Nájera, Isabel, Bertasso, Anne, Hammond, Janet, Kindrick, Amy, Morcos, Peter N., Smith, Patrick, Stancic, Saray, and Shulman, Nancy S.

Published
2015
Full Text
View/download PDF

2. Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment

Author

Zhang, Xiaoping, Lin, Tiffany, Bertasso, Anne, Evans, Claire, Dorr, Albert, Kolis, Stanley J., Salgo, Miklos, and Patel, Indravadan

Subjects
Pharmacokinetics -- Research, Pediatric pharmacology -- Research, Enfuvirtide -- Dosage and administration -- Research, Health, Drug therapy, Research, Dosage and administration
Abstract

The objective of this study was to characterize the population pharmacokinetics of enfuvirtide in HIV-1-infected children and adolescents. HIV-infected patients received combination antiretroviral therapy, including enfuvirtide 2.0 mg/kg subcutaneously, twice [...]

Published
2007

3. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks

Author

Troittier, Benoit, Walmsley, Sharon, Reynes, Jacues, Piliero, Peter, O'Hearn, Mary, Nelson, Mark, Montaner, Julio, Lazzarin, Adriano, Lalezari, Jacob, Katlama, Christine, Henry, Keith, Cooper, David, Clotet, Bonaventura, Arasteh, Keikawus, Delfraissy, Jean-Francois, Stellbrink, Hans-Jurgen, Lange, Joep, Kuritzkes, Daniel, Eron, Joseph J., Jr., Cohen, Calvin, Kinchelow, Tosca, Bertasso, Anne, Labriola-Tompkins, Emily, Shikhman, Anna, Atkins, Belinda, Bourdeau, Laurence, Natale, Christopher, Hughes, Fiona, Jain Chung, Guimaraes, Denise, Drobnes, Claude, Bader-Weder, Silvia, DeMasi, Ralph, Smiley, Lynn, and Salgo, Miklos P.

Subjects
Antiviral agents -- Research, HIV infection -- Care and treatment, Drug therapy, Combination, Health
Abstract

The analysis of pooled safety data from the pivotal phase three T-20 Versus Optimized Background Regimen Only (TORO) trials indicates that enfuvirtide is a well-tolerated antiretroviral agent with a maintained safety profile over 48 weeks in treatment-experienced HIV-1-infected adults. It is found that the rates of other adverse agents favored enfuvirtide or were generally comparable between treatments.

Published
2005

5. Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM‐SVR study

Author

Gane, Edward J., primary, Pockros, Paul J., additional, Zeuzem, Stefan, additional, Marcellin, Patrick, additional, Shikhman, Anna, additional, Bernaards, Coen, additional, Zhou, Julian, additional, Yetzer, Ellen S., additional, Ballester, Rosa, additional, Dwyer, Cindy, additional, Tong, Xiao, additional, Nájera, Isabel, additional, Bertasso, Anne, additional, Hammond, Janet, additional, Kindrick, Amy, additional, Morcos, Peter N., additional, Smith, Patrick, additional, Stancic, Saray, additional, and Shulman, Nancy S., additional

Published
2014
Full Text
View/download PDF

6. Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device

Author

Varunok,Peter, Lawitz,Eric, Beavers,Kimberly L, Matusow,Gary, Leong,Ruby, Lambert,Nathalie, Bernaards,Coen, Solsky,Jonathan, Brennan,Barbara J, Wat,Cynthia, Bertasso,Anne, Varunok,Peter, Lawitz,Eric, Beavers,Kimberly L, Matusow,Gary, Leong,Ruby, Lambert,Nathalie, Bernaards,Coen, Solsky,Jonathan, Brennan,Barbara J, Wat,Cynthia, and Bertasso,Anne

Abstract

Peter Varunok1, Eric Lawitz2, Kimberly L Beavers3, Gary Matusow4, Ruby Leong5, Nathalie Lambert6, Coen Bernaards7, Jonathan Solsky5, Barbara J Brennan5, Cynthia Wat8, Anne Bertasso51Gastroenterology Associates, Poughkeepsie, NY, USA; 2Alamo Medical Research, San Antonio, TX, USA; 3Asheville Gastroenterology, Asheville, NC, USA; 4Gastroenterology Group, South Jersey, NJ, USA; 5Roche, Nutley, NJ, USA; 6Roche, Basel, Switzerland; 7Roche, San Francisco, CA, USA; 8Roche, Welwyn, UKBackground: Peginterferon alfa-2a (40 kDa) is currently administered using a prefilled syringe. The peginterferon alfa-2a disposable autoinjector is a new safety-engineered device designed to facilitate injection and reduce the risk of needlestick injuries. The analysis of two open-label Phase I trials evaluated the pharmacokinetics, successful administration, and tolerability of peginterferon alfa-2a when using the autoinjector. The studies were performed to support the filing and registration of the autoinjector device.Methods: In trial 1, 50 healthy adult subjects received one 180 µg dose of peginterferon alfa-2a via the autoinjector. Serial blood samples were collected predose, up to 336 hours following drug administration, and at follow-up (28 ± 3 days post-dosing) for noncompartmental pharmacokinetic analysis. Trial 2 randomized 60 adult patients with chronic hepatitis C to 180 µg peginterferon alfa-2a once weekly by the autoinjector or prefilled syringe for 3 weeks followed by the alternative device (prefilled syringe or autoinjector, respectively) for 3 weeks. Patients also received ribavirin. Administration by the devices was evaluated under direct observation by a study staff member and by patient subjective assessment.Results: In trial 1, following a single dose of peginterferon alfa-2a, the maximum plasma concentration was 16.1 ± 5.3 ng/mL (mean ± standard deviation), and area under the concentration time curve (0–168 ho

Published
2011

7. Adherence to Enfuvirtide and Its Impact on Treatment Efficacy

Author

Rockstroh, Jürgen, primary, DeJesus, Edwin, additional, Donatacci, Lucille, additional, Wat, Cynthia, additional, Bertasso, Anne, additional, Labriola-Tompkins, Emily, additional, Shikhman, Anna, additional, Atkins, Belinda, additional, Guimaraes, Denise, additional, Wilkinson, Martin, additional, Thommes, James, additional, Rowell, Lucy, additional, Demasi, Ralph, additional, and Salgo, Miklos, additional

Published
2008
Full Text
View/download PDF

9. Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks

Author

Trottier, Benoit, primary, Walmsley, Sharon, additional, Reynes, Jacques, additional, Piliero, Peter, additional, O'Hearn, Mary, additional, Nelson, Mark, additional, Montaner, Julio, additional, Lazzarin, Adriano, additional, Lalezari, Jacob, additional, Katlama, Christine, additional, Henry, Keith, additional, Cooper, David, additional, Clotet, Bonaventura, additional, Arastéh, Keikawus, additional, Delfraissy, Jean-François, additional, Stellbrink, Hans-Jürgen, additional, Lange, Joep, additional, Kuritzkes, Daniel, additional, Eron, Joseph J, additional, Cohen, Calvin, additional, Kinchelow, Tosca, additional, Bertasso, Anne, additional, Labriola-Tompkins, Emily, additional, Shikhman, Anna, additional, Atkins, Belinda, additional, Bourdeau, Laurence, additional, Natale, Christopher, additional, Hughes, Fiona, additional, Chung, Jain, additional, Guimaraes, Denise, additional, Drobnes, Claude, additional, Bader-Weder, Silvia, additional, DeMasi, Ralph, additional, Smiley, Lynn, additional, and Salgo, Miklos P, additional

Published
2005
Full Text
View/download PDF

17. Porins and lipopolysaccharide of Escherichia coli ATCC 25922 and isogenic rough mutants

Author

Rivera, Mildred, Bertasso, Anne, McCaffrey, Catherine, and Georgopapadakou, Nafsika H.

Abstract

The lipopolysaccharide and porin profile of Escherichia coli ATCC 25922, a smooth strain commonly used in antibiotic susceptibility testing, and five isogenic rough mutants was examined. The lipopolysaccharide of the parent strain had the characteristic ladder pattern on polyacrylamide gels, while that of the mutants appeared similar to chemotypes Ra and Rc of Salmonella typhimurium with some changes in chemical composition. Of the porins, OmpC appeared markedly reduced in the parent strain while OmpF appeared markedly reduced in the mutants. In addition, a new outer-membrane protein of size intermediate to that of OmpC and OmpF was detected in all mutants. Neither parent nor mutants were susceptible to the LPS core-specific P1 phage or the porin-specific PA2 and K20 phages.

Published
1993
Full Text
View/download PDF

18. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.

Author

Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, and Salgo MP

Subjects
Adult, Diarrhea, Drug Therapy, Combination, Enfuvirtide, Fatigue, HIV Envelope Protein gp41 administration & dosage, HIV Envelope Protein gp41 therapeutic use, HIV Fusion Inhibitors administration & dosage, HIV Fusion Inhibitors therapeutic use, Humans, Lymphatic Diseases, Nausea, Peptide Fragments administration & dosage, Peptide Fragments therapeutic use, Pneumonia, Anti-HIV Agents therapeutic use, HIV Envelope Protein gp41 adverse effects, HIV Fusion Inhibitors adverse effects, HIV Infections drug therapy, HIV-1, Peptide Fragments adverse effects
Abstract

Background: Antiretroviral tolerability is a critical factor contributing to treatment outcome. The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety and efficacy of enfuvirtide in treatment-experienced HIV-1-infected patients., Methods: A total of 997 patients were randomized at a 2:1 ratio to an optimized background antiretroviral regimen plus enfuvirtide (n = 663) or an optimized background regimen alone (control group; n = 334). Control patients could switch to enfuvirtide on virologic failure., Results: In total, 26.5% of patients randomized to enfuvirtide and 36.6% to the control group discontinued study treatment before week 48; the percentage of patients withdrawn for safety reasons (including adverse events [AEs], deaths, and laboratory abnormalities) was 14.0% in the enfuvirtide group and 11.6% in the control group. Injection site reactions (ISRs) occurred in 98% of enfuvirtide patients and led to treatment discontinuation in 4.4%. Treatment-related (defined as possibly, probably, or remotely) AE rates per 100 patient-years were lower with enfuvirtide (96.2) than in the control group (149.9); diarrhea, nausea, and fatigue, the most frequently reported AEs, were significantly less frequent with enfuvirtide than in the control group. Pneumonia was significantly more frequent in patients treated with enfuvirtide (6.7 vs. 0.6 events per 100 patient-years), although the incidence was within expected ranges for this population. Lymphadenopathy was also higher in enfuvirtide-treated patients (7.1 vs. 1.2 events per 100 patient-years) for control patients., Conclusion: The addition of enfuvirtide to an optimized background regimen does not exacerbate AEs commonly associated with antiretrovirals. ISRs limited treatment in <5% of patients.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results